Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WAYPOINT phase 3 trial of tezepelumab in severe chronic rhinosinusitis with nasal polyps
MOH_2021-07-27_010152Phase 3Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic rhinosinusitis with nasal polyps (CRSwNP) comparing Tezepelumab with Placebo (2 arms). Primary endpoints: Change in total nasal polyp score and Change in nasal congestion. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on MOH_2021-07-27_010152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-07-27_010152.